Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Forms Molecular Dx Joint Venture in Singapore

NEW YORK (GenomeWeb News) – Qiagen is starting a joint venture in Singapore with Bio*One Capital, a biomedical investment management company based in that country, that will develop molecular diagnostic assays for genetic and infectious diseases, the firms said today.
The venture, called Dx Assays, should be operational by early 2008 and will be staffed with over 30 researchers, the companies said. 
Qiagen said it expects the venture will broaden its molecular assay portfolio and expand its market reach in Asia, which accounted for around 10 percent of the company’s overall net sales last year.
Dx Assays plans to collaborate with research institutes and hospitals in the molecular diagnostics field to “bring a strong commercial perspective to the ongoing research activities here,” said Swee-Yeok Chu, CEO of Bio*One Capital.
"The in-depth expertise and talent pool in biomedical research makes Singapore an ideal location for a center for assay development,” Qiagen CEO Peer Schatz added in a statement.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.